Table 3.
| a. Distributions of training and test substances for LLNA models | ||||||
|---|---|---|---|---|---|---|
| Potency categorya | Entire set (n = 120) | Training set (n = 94) | Test set (n = 26) | |||
| Number | % | Number | % | Number | % | |
| 1A | 35 | 29 | 28 | 30 | 7 | 27 |
| 1B | 52 | 43 | 40 | 42 | 12 | 46 |
| Neg | 33 | 28 | 26 | 28 | 7 | 27 |
| b. Distributions of training and test substances for human models | ||||||
|---|---|---|---|---|---|---|
| Potency categorya | Entire set (n = 87) | Training set (n = 63) | Test set (n = 24) | |||
| Number | % | Number | % | Number | % | |
| 1A | 26 | 30 | 19 | 30 | 7 | 29 |
| 1B | 31 | 36 | 22 | 35 | 9 | 38 |
| Neg | 30 | 34 | 22 | 35 | 8 | 33 |
LLNA, murine local lymph node assay.
a
The 1A category consists of strong sensitizers and the 1B category consists of weak sensitizers based on the Globally Harmonized System of Classification and Labeling of Chemicals (UN 2015); Neg, nonsensitizer.